The Chinese Government has approved early-stage human clinical trials of two vaccine candidates against Covid-19, according to state news agency Xinhua. The candidates are being developed by a Beijing subsidiary of Sinovac Biotech and by the Wuhan Institute of Biological Products.
RedHill Biopharma has reported preliminary data from a compassionate use programme of opaganib to treat Covid-19 patients in Israel. The results revealed that two initial patients showed clinical improvement within days after treatment-initiation with opaganib plus standard of care.
Celltrion Group has identified the most promising Covid-19 antibody therapy candidates among the initial 300 discovered in alliance with the Korea Centers for Disease Control and Prevention (KCDC). The next steps for the candidates are cell-line development and mass production, followed by efficacy and toxicity testing in mice and non-human primates.
Athersys has received the US Food and Drug Administration (FDA) approval to conduct a Phase II/III clinical trial of MultiStem therapy to treat moderate to severe acute respiratory distress syndrome caused by Covid-19. The open-label, multi-centre, randomised study will assess the therapy’s safety and efficacy.